natgillin/translations-raw huggingface dataset:
A compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein Rb is-NRxRy, wherein Rx and Ry are independently selected from hydrogen, C1-4alkoxyC1-4alkyl, C1-6alkyl, C3-7cycloalkyl, hydroxyC1-4alkyl, and trideuteromethyl, wherein the alkyl part of the (C3-7cycloalkyl)C1-4alkyl can be optionally substituted with a C1-4alkoxy group. 
Tvar iz patentnog zahtjeva 5, ili njena farmaceutski prihvatljiva sol, pri čemu je Rb –NRxRy, pri čemu su Rx i Ry nezavisno odabrani između vodika, C1-4alkoksiC1-4alkila, C1-6alkila, C3-7cikloalkila, hidroksiC1-4alkila i trideuterometila, pri čemu alkilni dio (C3-7cikloalkil)C1-4alkila može opcionalno biti supstituiran s C1-4alkoksi grupom.
The method of item 45, wherein the eye disorder is uveitis, macular degeneration, glaucoma, diabetic macular edema, blepharitis, diabetic retinopathy, a disease or disorder of the corneal endothelium, post-surgical inflammation, dry eye, allergic conjunctivitis, or a form of conjunctivitis. 
Farmaceutski pripravak za uporabu prema zahtjevu 45, naznačen time da je poremećaj oka uveitis, makularna degeneracija, glaukom, dijabetički makularni edem, blefaritis, dijabetička retinopatija, bolest ili poremećaj endotela rožnice, upala nakon operacije, suho oko, alergijski konjunktivitis, ili oblik konjunktivitisa.
When the bottle is installed the flange on the bottle rests against the upper surface of the segments of the rosette, and manipulations with the outlet opening can be performed in this phase. 
Kad je boca postavljena, prirubnica na boci dolazi na gornju površinu segmenata rozete, i u toj fazi se mogu izvršiti potrebne radnje na izlaznom otvoru.
The ball spline nuts 42, 43 are disposed on the ball spline shaft 40 and are connected to the shaft for rotation therewith by the balls 66 disposed between them in the manner previously described. 
Kuglasto-klinaste matice (42), (43) su smještene na kuglasto-klinastoj osovini (40) i spojene su na nju za okretanje pomoću kuglica (66) na način kako je prethodno bilo opisano.
The vector of claim 4, wherein the pathogen specific antigen is derived from human immunodeficiency virus, simian immunodeficiency virus, herpes simplex virus type 1(HSV1), herpes simplex virus type 2 (HSV2), hepatitis B virus, human papillomavirus, or Mycobacterium tuberculosis. 
Vektor prema patentnom zahtjevu 4, naznačen time, da je patološki specifičan antigen izveden iz virusa humane imunodeficijencije, simian virusa imunodeficijencije ii Mycobacterium tuberculosis.
A compound having Formula II: or a stereoisomer, tautomer; or pharmaceutically acceptable salt thereof, wherein, W is CRw or N, wherein Rw is selected from the group consisting of 
NaM Na Hi ili njegov stereoizomer, tautomer ili farmaceutski prihvatljiva sol, gdje W je CRy ili N, gdje je Ry odabran iz skupine koja sadrži
unit cell parameters substantially equal to the following at −173° C.: 
(c) parametre jedinične ćelije, koji su jednaki sljedećim, na -173C:
Also the aldehydes are either known or can be prepared by known methods. 
Također su aldehidi ili poznati ili se mogu načiniti poznatim postupcima.
an HIC chromatogram in which (i) peak 3 is absent, and (ii) peak 2 represents greater than 95 wt% of the composition; 
(A) HIC kromatogram kod koga je (i) pik 3 odsutan, i (ii) pik 2 predstavlja više od 95 tež% kompozicije;
A process according to claim 1 or claim 2, wherein solid material is obtained from a process selected from the group consisting of mechanical micronization, milling, jet milling, grinding, rapid precipitation, freeze drying, lyophilisation, rapid expansion of supercritical solutions, spray drying or mixtures thereof, preferably spray drying. 
Postupak u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, pri čemu je čvrsti materijal dobiven 1z postupka odabranog iz grupe koja se sastoji od mehaničke mikronizacije, mljevenja, mlaznog mljevenja, drobljenja, brzog taloženja, sušenja smrzavanjem, liofilizacije, brze ekspanzije superkritičnih otopina, sušenja raspršivanjem ili njihovih kombinacija, poželjno sušenja raspršivanjem.
“*” means a chiral center with absolute stereochemistry (R) or (S); and resolving the resulting diastereomeric mixture via crystallization to provide the compound of formula (II). 
"*" znači kiralni centar s apsolutnom stereokemijom (R) ili (S); te od rastavaranja rezultirajuće dijastereomerne smjese putem kristalizacije, za dobivanje spoja formule (II).
The recombinant molecule of claim 6, wherein said nucleic acid sequence encoding said adenoviral E1A protein and said nucleic acid sequence encoding said adenoviral E1B protein are separated by at least 34.5 kb. The recombinant molecule of claim 5, wherein said molecule is linear. A set of at least two nucleic acid molecules comprising: 
Rekombinantna molekula ili skup od barem dvije molekule nuklemske kiseline prema zahtjevu 5, naznačena time da su navedena sekvenca nukleinske kiseline koja kodira El A protein i sekvenca nukleinske kiseline koja kodira barem jedan E1B protein odvojene sa barem 34.5 kb,
As with the previous embodiments the piercing can be accomplished without the outer sealing 17, e.g. 
Kao i u prethodnim izvedbama, probijanje se može provesti bez vanjske brtve 17, npr.
unblocking the flow communication between the first volume (V1) and the second volume (V2) inside the enclosure with the at least one blocking unit (30). 
- deblokiranje protočne komunikacije između prvog volumena (V1) 1 drugog volumena (V2) unutar kućišta s najmanje jednom jedinicom za blokiranje (30).
is an ethyl group. 
- R2 je etilna skupina.
providing of a vitamin D tracer composition which is coupled to a solid phase; 
(c) dodavanja spoja za vizualizaciju vitamina D, konjugiranog s čvrstom fazom;
Preferably, the antibody selected in step (b) inhibits the binding of a HLA-c allele molecule having a Lys residue at position 80 to a human KIR2DL1 receptor, and the binding of a HLA-C allele molecule having an Asn residue at position 80 to human KIR2DL2/3 receptors. 
Lys ostatak na položaju 80, za humani KIR2DLI receptor, i vezanje HLA-C alel molekule, koja ima Asn ostatak na položaju 80, za humane KIR2DL2/3 receptore.
reacting a compound of Formula II: 
reakciju spoja formule II
Effect of various concentration of Compound 4 in a rat tumor model Group Treatment 
Učinak različitih koncentracija spoja 4 u modelu tumora štakora. Skupina Tretman
The capture complex of claim 1, wherein the wherein the capture entity is an antigen or antigenic peptide from an organism selected from the group consisting of heartworm, Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia ewingii, Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, Anaplasma phagocytophilum, Anaplasma platys, feline leukemia virus, parvovirus, influenza A strain, influenza B strain, avian influenza virus, respiratory syncytial virus, Legionella, adenovirus, rotavirus, feline immunodeficiency virus, human immunodeficiency virus, and Group A Streptococcus. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što je navedeni antigen ili antigeni peptid iz organizma kojeg se bira iz skupine koju čine srčana glista, Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia ewingii, Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, Anaplazma phagocytophilum, Anaplazma platys, virus mačje leukemije, parvovirus, soj A influence, soj B influence, virus ptičje influence, respiratorni sincicijski virus, Legionella, adenovirus, rotavirus, virus mačje imunodeficijencije, virus ljudske imunodeficijencije, te skupina A streptokoka.
The antitumor agent for use according to claim 1, wherein the combination drug containing trifluridine and tipiracil hydrochloride in a molar ratio of 1:0.5 is administered, using a reduced amount of trifluridine, at a dose in the range of 70 mg/m2/day using a reduced amount of trifluridine, wherein preferably irinotecan hydrochloride hydrate is administered at a dose in the range of 75 to 120 mg/m2/day. 
Antitumorni agens za primjenu u skladu sa patentnim zahtjevom 1, gdje kombinirani lijek koji sadrži trifluridin i tipiracil hidroklorid u molarnom odnosu od 1:0.5 je administriran, primjenjujući smanjenu količinu trifluriđina, u dozi u opsegu od 70 mg/m"/dan primjenjujući smanjenu količinu trifluridina, gdje poželjno irinotekan hidroklorid hidrat je administriran u dozi u opsegu od 75 do 120 mg/m?/dan.
common connection aperture (91) opened and right and left exhaust tract aperture opened; 
priključak otvoren i desni i lijevi otvor ispušnog kraka otvoreni; i/ili
Structure in accordance with claim 15, in which said elements of the surround are fixed to the counter-frame with a joint coupling and/or by gluing and/or by screws and/or by clamps or profiled sheet metal. 
Struktura prema zahtjevu 14, naznačena time da su navedeni elementi (12’,12a,12b) okruženja (12) fiksirani na protuokvir (10) pomoću spojke i/ili lijepljenja i/ili vijaka i/ili spona ili profiliranog lima.
The antibody of claim 3, wherein the VL comprises SEQ ID NO:67 and the VH comprises SEQ ID NO:69. 
Protutijelo sukladno patentnom zahtjevu 2, naznačeno time, da VL sadrži SEK ID BR: 63 i VH sadrži SEK ID BR: 66.
A process for preparing a compound according to formula (1), or tautomer, or salt thereof, 
Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
In a preferred embodiment the marker vaccine of the present invention is characterised in that the modified virus is not produced via recombinant DNA methods. 
2. Marker cjepivo u skladu s prethodnim patentnim zahtjevom, naznačeno time što modificirani virus ne izražava rekombinantne sljedove nukleinske kiseline.
In another preferred aspect, the culturing takes place in a shake flask or fermentor, preferably a fermentor. 
Postupak prema zahtjevu 1, naznačen time, da se kultiviranje odvija u bocama na tresilici ili u napravi za fermentiranje.
In this variant a protection against short circuit currents is added by inserting a current transformer 300 on conductor 14. 
U ovoj varijanti dodana je zaštita od struja kratkog spoja dodavanjem transformatora 300 na vodič 14.
The injectable preparation according to any one of Items 1 to 3 and 5 to 8, or the composition according to any one of Items 4 to 8, wherein the poorly soluble drug is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof. 
Injekcijski pripravak prema bilo kojem od zahtjeva 1 do 3 i 5 do 8, ili pripravak prema bilo kojem od patentnih zahtjeva 4 do 8, naznačen time što slabo topivi lijek je 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoksi]-1H- kinolin-2-on ili njegovu sol.
A granulate comprising a mixture of mannitol and sorbitol in a ratio by weight of between 70:30 and 97:3, said granulate having a residual moisture content of less than 0.20% by weight relative to the weight of the same granulate, obtained after granulating by introducing air at a temperature below 80°C with a moisture content of less than 5000 ppm for less than 30 minutes. 
PATENTNI ZAHTJEVI Granulat sadrži mješavinu manitola i sorbitola u težinskom omjeru između 70:30 1 97:3, naznačeni granulat ima ostatak vlage manji od 0,20 težinskih % u odnosu na težinu istog granulata dobivenog nakon granuliranja uvođenjem zraka pri temperaturi ispod 80%, sa sadržajem vlage manjim od 5000 ppm na manje od 30 minuta.
A composition according to claim 2, for oral administration. A composition according to claim 2, for parenteral administration. 
Sastav prema zahtjevu 2, naznačen time, da je namijenjen za oralnu primjenu ili za parenteralnu primjenu.
The receiver of claim 4 or 5, wherein the block includes constellation values in the four sub-blocks when a value of the L1 TI mode information corresponds to '10' and wherein the block includes constellation values in the eight sub-blocks when the value of the L1 TI mode information corresponds to `11'. 
Prijamnik iz patentnog zahtjeva 4 ili 5, pri čemu blok uključuje konstelacijske vrijednosti u četiri podbloka kada vrijednost informacije vrste L1 TI odgovara '10' i pri čemu blok uključuje konstelacijske vrijednosti u osam podblokova kada vrijednost informacije vrste L1 TI odgovara '11'.
Amino acid is selected from arginine, glycine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophane, methionine, serine, proline, cysteine / cystine and suitable combination thereof; 
aminokiselina je odabrana između arginina, glicina, lizina, histidina, glutaminske kiseline, asparaginske kiseline, izoleucina, leucina, alanin, fenilalanin, tirozin, triptofan, metionin, serin, prolin, cistein / cistin i njihove pogodne kombinacije;
under Mitsunobu reaction conditions, to give a compound of formula (VIII): 
(VID pri uvjetima Mitsunobuove reakcije, pri čemu nastaje spoj formule (VIII): i
The composition according to claim 1, wherein the composition further comprises one or more of abrasives, absorbents, fragrances, pigments, colorings/colorants, essential oils, anti-caking agents, antifoaming agents, antimicrobials, binders, biological additives, buffering agents, bulking agents, chelating agents, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, emollients, external analgesics, film formers or materials, opacifying agents, pH adjusters, preservatives, propellants, reducing agents, sequestrants, skin cooling agents, skin protectants, thickeners/viscosity modifiers, vitamins, or combinations thereof. 
jedan ili više dodatnih sastojaka, koje se bira iz skupine koju čine abrazivi, apsorbensi, mirisi, pigmenti, boje/bojila, eterična ulja, sredstva protiv zgrušavanja, sredstva protiv pjenjenja, antimikrobne tvari, veziva, biološki aditivi, puferska sredstva, punila, kelirajuća sredstva, bojila, kozmetički astringensi, kozmetički biocidi, denaturansi, medikamentozni astringensi, sredstva za vlaženje, vanjski analgetici, sredstva ili materijali koji prave filmove, sredstva za neprozirnost, sredstva za podešavanje pH, konzervansi, propelansi, reducensi, sekvestransi, sredstva za hlađenje kože, sredstva za zaštitu kože, ugušćivači/modifikatori viskoznosti, vitamini, i njihove kombinacije.
the determination of the mean offset of the symbols of the sequence. 
- < određivanje srednjeg odlaznog pomaka simbola sekvence.
The material of claim 1, wherein the volatile component comprises solid precursors to the gaseous form of the volatile compound. The material of claim 1, wherein the volatile component does not comprise a substance with a boiling point below 0° C. 
Postupak za primjenu materijala koji se aktivira vlagom na pakiranje, koji obuhvaća dispergiranje hlapljive komponente koja ima točku vrenja između 40°C i 300°C u vodenoj otopini ili disperziji vezivne komponente da bi se dobila smjesa;
said spr0565 antigen comprises an amino acid sequence: (a) having 80% or more identity to SEQ ID NO: 3; and/or (b) comprises a fragment of at least 10 consecutive amino acids, comprising an epitope of SEQ ID NO: 3; 
navedeni antigen spr0565 sadrži aminokiselinski slijed: (a) koji je 80% ili više identičan SEQ ID NO: 3; i/ili (b) sadrži fragment od najmanje 10 uzastopnih aminokiselina, koji sadrži epitop iz SEQ ID NO: 3;
A process according to claim 1, further comprising providing at least one controlled cooling step (13, 13) during and/or after said rolling step. 
Postupak prema zahtjevu 1, naznačen time što dalje omogućuje najmanje jedan kontrolirani korak hlađenja (13, 13) za vrijeme i/ili nakon spomenutog koraka valjanja
Preferred flavorants include, but are not limited to, cherry, strawberry, fruit punch, grape, cream, vanilla, chocolate, mocha, spearmint, cola, and the like. 
Povoljni korigensi okusa uključuju, ali nisu ograničeni na, višnju, jagodu, voćni punč, grejp, vrhnje, vaniliju, čokoladu, kavu, spearmint, kolu i slično.
A vaccine comprising the recombinant virus of any one of claims 1 to 6, in unit dose form. 
Cjepivo sadrži rekombinantni virus iz bilo kojeg od patentnih zahtjeva 1 do 6, u jediničnom obliku doziranja.
A continuous rolling mill for rolling an article defining a rolling axis X, comprising at least two rolling stations arranged in series along the rolling axis X, wherein at least one rolling station comprises: 
Kontinuirana valjaonica (20) za valjanje artikla (44), gdje je zadana os valjanja X, koja se sastoji od najmanje dva valjaonička stana (22), smještena u niz duž osi valjanja X, gdje najmanje jedan valjaonički stan (22) sadrži:
The compound of Formula XXVII can be deprotected to form a compound of Formula XXVIII, which on oxidation can give a compound of Formula XXIX. 
Formula IX čime se dobiva spoj Formule XXVII: Formula XXII b. skidanje zaštite sa spoja Formule XXVII, čime se dobiva spoj Formule XXVIII:
This phenomenon, a characteristic application of the action/reaction principle, indicates the impulse that causes the gun to move back due to the impulse that the gun imparts to the bullet when firing it. 
Ovaj fenomen, koji je karakteristična primjena principa akcije/reakcije, ukazuje na impuls koji uzrokuje da se oružje pomakne prema natrag zbog impulsa koji oružje daje metku kada ga ispali.
Another aspect of the present invention includes an in vitro method for producing activated T cells, the method comprising contacting in vitro T cells with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate the T cell in an antigen specific manner, wherein the antigen is a peptide according to the invention. Preferably a sufficient amount of the antigen is used with an antigen-presenting cell. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnog spoja koji oponaša stanicu koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s bilo kojim patentnim zahtjevom od 1 do 3.
R26A and R27A are independently -C=N or an optionally substituted substituent selected from the group consisting of C2-8 organylcarbonyl, C2-8 alkoxycarbonyl and C2-8 organylaminocarbonyl; 
Ri R2" su neovisno -C=N ili po izboru supstituiran supstituent odabran iz skupine koja sadrži C,. sorganilkarbonil, C, g alkoksikarbonil i C, gorganilaminokarbonil;
In another embodiment, in formula (VII), R42 is selected from the group consisting of lower alkyl, lower cycloalkyl, —C(O)N(R27)2, or —C(O)OH, wherein R27 is —H or a lower alkyl. 
Spoj prema zahtjevu 19, pri čemu Xu, je NR, 1 R4, je izabran iz skupine koju čine -H, niži alkil, niži cikloalkil, - C(O)N(R27)2, 1 -C(O)OH, pri čemu svaki R2; je nezavisno -H ili niži alkil.
For instance, unlike sucrose, maltitol and isomalt, like other polyols, do not brown or caramelize. 
Na primjer, za razliku od saharoze, maltitol i izomalt, kao ni ostali polioli, ne poprimaju smeđu boju i ne karameliziraju se.
A method for the synthesis of Y,δ-dihydroxyisoleucine 1, or of a synthon for compound 1, comprising the step of methylating compound 3 with methyl iodide in the presence of lithium bis(trimethylsilyl)amide (LHMDS). 
Postupak sinteze Y,δ-dihidroksiizoleucina 1, ili sintona spoja 1, naznačen time, da obuhvaća korak metilacije spoja 3 ili 3* s metil jodidom u prisutnosti litij bis(trimetilsilil)amida (LHMDS). [image]
The jack system of claim 1, comprising: three or more opposing and spaced apart jacks laterally facing each other, with said one or more structures to be selectively raised and lowered, spaced therebetween. 
Sustav dizalica (10, 100) sukladno zahtjevu 2, sastojeći se od tri ili više razmaknutih dizalica (50,150) lateralno okrenutih jedna prema drugoj, s cijevima ili policama za kablove (12,112) koje se selektivno podižu i spuštaju, razmaknutim između njih.
Atomiser according to claims 2, 22 and 25, characterised in that the locking device (78) is arranged on the part or that in the first and/or second locked state rotation of the part relative to the atomiser (1) and/or operation of the locking element (8) are blockable. 
Raspršivač prema zahtjevima 7 19, naznačen time, da je zaporni uređaj (78) raspoređen na pokretnom ili okretnom dijelu ili da su blokirani, u zatvorenom stanju, i okretanje dijela u odnosu na raspršivač (1) i/ili radna operacija zapornog elementa (8).
The process according to claim 1, wherein the EPA and DHA ethyl esters assay is at least 80% by weight, the EPA ethyl ester assay being at least 40% by weight and the DHA ethyl ester assay being at least 34% by weight; the total w-3, acids ethyl esters assay being at least 90% by weight. 
Postupak prema patentnim zahtjevima 6-15, u kojem je udio EPA i DHA ctil cstera najmanje 80 % po masi, Udio EPA etil estera je najmanje 40 % po masi i udio DHA etil estera je najmanje 34 % po masi; ukupni udio etil estera 6-3 kiselina je najmanje 90 % po masi.
each such substituent optionally is substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: 
svaki takav supstituent je opcijski supstituiran s jednim ili više supstituenata neovisno odabranima iz skupine koju sačinjavaju alkil, alkenil, alkinil, karboksi, hidroksi, halo, amino, nitro, azido, okso, aminosulfonil, alkiloksikarbonil, alkeniloksikarbonil, alkiniloksikarbonil, alkilkarboniloksi, alkenilkarboniloksi, alkinilkarboniloksi, alkiloksi, alkeniloksi, alkiniloksi, karbociklil, heterociklil, cijano i aminokarbonil, gdje:
The composition of any one of claims 1-6, wherein the polypeptide is a fusion protein comprising an SAP domain and one or more heterologous domains. 
Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time, da je polipeptid fuzijski protein koji sadržava domenu SAP i jednu ili više heterolognih domena.
The overpressure was of 500 mbars. 
Tlak je iznosio 500 mbara.
A combination according to claim 5 wherein the B2 agonist is formoterol fumarate. 
Kombinacija sukladno patentnom zahtjevu 4, naznačena time, da je kortikosteroid beklometazon dipropionat.
removing from the system at least part of the treated mass through a branch-off provided in the return pipe when a predetermined grinding fineness has been obtained, and 
uklanjanja iz sustava u najmanju ruku dijela obrađene mase kroz ogranak koji se nalazi u povratnoj liniji kada se postigne zadanu finoću mljevenja, i
Wind system (1) according to claim 2, characterised in that said spring is compressed due to said tension of said rope (4). 
Vjetreni sustav (1) prema zahtjevu 1, naznačen time da je spomenuti sustav za vraćanje zmajeva (8) napravljen od jedne konstrukcije rešetkastog tipa.
is phenyl or pyridyl, which is para-substituted by Hal and/or meta-substituted by Hal or LA, and pharmaceutically acceptable salts, solvates, solvates of salts, thereof. 
je fenil ili piridil, koji je para-supstituiran s Hal i/ili meta-supstituiran s Hal ili LA, i njihove farmaceutski prihvatljive soli, solvati ili solvati soli.
Simulations and tests have made clear that the teaching of this patent cannot be applied on industrial scale. 
Simulacije i ispitivanja su jasno pokazali da se učenje tog patenta ne može primijeniti u industrijskim razmjerima.